PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 2,514 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew Klein sold 2,514 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $76.45, for a total value of $192,195.30. Following the completion of the transaction, the chief executive officer directly owned 394,453 shares in the company, valued at approximately $30,155,931.85. This trade represents a 0.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

PTC Therapeutics Stock Up 0.1%

Shares of NASDAQ PTCT opened at $77.59 on Tuesday. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $87.50. The firm has a market cap of $6.23 billion, a PE ratio of 9.06 and a beta of 0.49. The business has a fifty day simple moving average of $76.81 and a two-hundred day simple moving average of $63.11.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million for the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business’s revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.39) EPS. On average, research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on PTCT shares. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Royal Bank Of Canada downgraded shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their price objective for the stock from $82.00 to $91.00 in a research note on Monday, December 1st. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 target price on shares of PTC Therapeutics in a research report on Thursday. TD Cowen lifted their price target on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Finally, Jefferies Financial Group upped their price objective on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $77.27.

Institutional Trading of PTC Therapeutics

Institutional investors have recently made changes to their positions in the business. AlphaQuest LLC boosted its position in PTC Therapeutics by 337.7% in the second quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 6,102 shares during the last quarter. Vise Technologies Inc. acquired a new stake in PTC Therapeutics during the 2nd quarter valued at approximately $486,000. Prudential Financial Inc. boosted its holdings in shares of PTC Therapeutics by 35.5% in the 2nd quarter. Prudential Financial Inc. now owns 84,250 shares of the biopharmaceutical company’s stock valued at $4,115,000 after acquiring an additional 22,060 shares during the last quarter. Hussman Strategic Advisors Inc. increased its stake in shares of PTC Therapeutics by 200.0% in the second quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the biopharmaceutical company’s stock worth $3,077,000 after acquiring an additional 42,000 shares during the period. Finally, Y Intercept Hong Kong Ltd raised its holdings in shares of PTC Therapeutics by 458.8% during the second quarter. Y Intercept Hong Kong Ltd now owns 27,832 shares of the biopharmaceutical company’s stock worth $1,359,000 after purchasing an additional 22,851 shares during the last quarter.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC provided a detailed update at the J.P. Morgan conference saying Sephience™ (sepiapterin) continues to scale — unaudited Q4 global Sephience revenue of $92.5M, unaudited 2025 total product & royalty revenue of ~ $823M (above guidance), 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth), and cash of ~$1.94B. These results and the 2026 guidance are the main bullish catalysts for the stock today. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Positive Sentiment: PTC presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available), reinforcing commercial execution and management commentary that supports the guidance and growth story. Conference Transcript
• Neutral Sentiment: Reported short interest data shows 0 shares (appears to be a data anomaly / NaN change) and a 0.0 days-to-cover — likely not meaningful to trading given the company’s volume and recent volatility. (Source: market data entry)
• Negative Sentiment: Multiple insiders disclosed open‑market sales between Jan 6–12 (CEO Matthew B. Klein, CFO Pierre Gravier, VP Mark Boulding, EVP/other officers including Eric Pauwels, Christine Utter, Lee Golden, Neil Almstead). Individual sales ranged from several dozen to several thousand shares; the CEO and other executives still retain large positions. Insider selling can create short‑term caution among investors even when shares are sold in open‑market transactions. Key filings/articles: CEO Form 4 (SEC). CEO Form 4 Eric Pauwels Form 4 (SEC). Pauwels Form 4 Media summary of CFO/CEO sales. Insider Selling Article

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.